Cargando…

US Food and Drug Administration international collaborations for cellular therapy product regulation

Cellular therapy products are an emerging medical product class undergoing rapid scientific and clinical innovation worldwide. These products pose unique regulatory challenges both for countries with existing regulatory frameworks and for countries where regulatory frameworks for cellular therapy pr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Arcidiacono, Judith A, Blair, Joan W, Benton, Kimberly A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3580429/ https://www.ncbi.nlm.nih.gov/pubmed/23021082 http://dx.doi.org/10.1186/scrt129

Ejemplares similares

Are the European Medicines Agency, US Food and Drug Administration, and Other International Regulators Talking to Each Other?
por: Teixeira, Tania, et al.
Publicado: (2019)

Compromise or Capitulation? US Food and Drug Administration Jurisdiction Over Tobacco Products
por: Glantz, Stanton A., et al.
Publicado: (2009)

Vaccines, pharmaceutical products, and bioterrorism: challenges for the U.S. Food and Drug Administration.
por: Zoon, K C
Publicado: (1999)

Cyberpharmacies and the role of the US Food And Drug Administration
por: Henney, Jane E
Publicado: (2001)

The US Food and Drug Administration’s Intersection with Dermatology
por: Luke, Markham C.
Publicado: (2022)

Pharmaceutical Drugs of Uncertain Value, Lifecycle Regulation at the US Food and Drug Administration, and Institutional Incumbency
por: HERDER, MATTHEW
Publicado: (2019)

US Food and Drug Administration regulatory updates in neuro-oncology
por: Mehta, Gautam U., et al.
Publicado: (2021)

Characteristics of Recent Generic Drug Approvals by the US Food and Drug Administration
por: Jiao, Kuo, et al.
Publicado: (2019)

Use of Extrapolation in New Drug Approvals by the US Food and Drug Administration
por: Feldman, Daniel, et al.
Publicado: (2022)

The U.S. Food and Drug Administration: Drug Information Resource for Formulary Recommendations
por: Marchand, Heidi C., et al.
Publicado: (2012)

US food and drug administration Indian site inspections: An experience
por: Mahajan, Pooja, et al.
Publicado: (2012)

Assessment of Public Opinion on Transparency at the US Food and Drug Administration
por: Azad, Tej D., et al.
Publicado: (2022)

The Significance of Information Posted on the U.S. Food and Drug Administration’s Website
por: Cook, G. Elliott, et al.
Publicado: (2013)

Exposure to US Cancer Drugs With Lack of Confirmed Benefit After US Food and Drug Administration Accelerated Approval
por: Parikh, Ravi B., et al.
Publicado: (2023)

Review of Evidence Supporting 2022 US Food and Drug Administration Drug Approvals
por: Kaplan, Robert M., et al.
Publicado: (2023)

The clinical pharmacogeneticist: An emerging regulatory scientist at the US Food and Drug Administration
por: Zineh, Issam, et al.
Publicado: (2010)

Why the Watchdog Won’t Bite: U.S. Food and Drug Administration Challenges
por: Lex, Joe
Publicado: (2016)

Time for the US food and drug administration approval of condoms for anal intercourse
por: Nguyen, Brian T., et al.
Publicado: (2019)

Recent Trends in Medicaid Spending and Use of Drugs With US Food and Drug Administration Accelerated Approval
por: Sachs, Rachel E., et al.
Publicado: (2021)

A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2020
por: Kayki-Mutlu, Gizem, et al.
Publicado: (2021)

A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2021
por: Kayki-Mutlu, Gizem, et al.
Publicado: (2022)

Analysis of Supportive Evidence for US Food and Drug Administration Approvals of Novel Drugs in 2020
por: Mitra-Majumdar, Mayookha, et al.
Publicado: (2022)

A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2022
por: Kayki-Mutlu, Gizem, et al.
Publicado: (2023)

Health outcomes coding trends in the US Food and Drug Administration's Sentinel System during transition to International Classification of Diseases‐10 coding system: A brief review
por: Nam, Young Hee, et al.
Publicado: (2021)

Time From Authorization by the US Food and Drug Administration to Medicare Coverage for Novel Technologies
por: Sexton, Zachary A., et al.
Publicado: (2023)

U.S. Food and Drug Administration-Certified Food Dyes as Organocatalysts in the Visible Light-Promoted Chlorination of Aromatics and Heteroaromatics
por: Rogers, David A., et al.
Publicado: (2020)

US Food and Drug Administration Accelerated Approval Program for Nononcology Drug Indications Between 1992 and 2018
por: Omae, Kenji, et al.
Publicado: (2022)

International collaboration: US panel members named
Publicado: (1994)

Pediatric dosing for locally acting drugs in submissions to the U.S. Food and Drug Administration between 2002 and 2020
por: Abulwerdi, Gelareh A., et al.
Publicado: (2023)

U.S. Food and Drug Administration: Review for the Emergency Physician of Approval Process and Limitations
por: Zuabi, Nadia, et al.
Publicado: (2016)

Cryptosporidiosis should be designated as a tropical disease by the US Food and Drug Administration
por: Choy, Robert K. M., et al.
Publicado: (2020)

Clinical benefit of immune checkpoint inhibitors approved by US Food and Drug Administration
por: Liang, Fei, et al.
Publicado: (2020)

A Proposed Framework for Patient-Focused Policy at the U.S. Food and Drug Administration
por: Kuehn, Carrie M.
Publicado: (2019)

Patient Participation in Clinical Trials of Oncology Drugs and Biologics Preceding Approval by the US Food and Drug Administration
por: Hutchinson, Nora, et al.
Publicado: (2021)

Association Between US Drug Price and Measures of Efficacy for Oncology Drugs Approved by the US Food and Drug Administration From 2015 to 2020
por: Miljković, Miloš D., et al.
Publicado: (2022)

Impact of the U.S. Food and Drug Administration Cardiovascular Assessment Requirements on the Development of Novel Antidiabetes Drugs
por: Hirshberg, Boaz, et al.
Publicado: (2011)

Prescription Drug Promotion from 2001-2014: Data from the U.S. Food and Drug Administration
por: Sullivan, Helen W., et al.
Publicado: (2016)

Impact of the US Food and Drug Administration registration of antiretroviral drugs on global access to HIV treatment
por: Chahal, Harinder Singh, et al.
Publicado: (2018)

Varenicline and Nicotine Replacement Use Associated With US Food and Drug Administration Drug Safety Communications
por: Desai, Ravi J., et al.
Publicado: (2019)

Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval
por: Cherla, Avi, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_hsh28lbhvtsnr02ta8kvdav9he